Novavax (NVAX) : During the past 4 weeks, traders have been relatively bearish on Novavax (NVAX), hence the stock is down -4.85% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.25% relative to the S&P 500. The 4-week change in the price of the stock is -4.49% and the stock has fallen -0.28% in the past 1 week.
Novavax, Inc. is up 33.97% in the last 3-month period. Year-to-Date the stock performance stands at -16.33%. The stock has recorded a 20-day Moving Average of 4.29% and the 50-Day Moving Average is 2.32%.
Novavax (NASDAQ:NVAX): The stock opened at $7.16 on Friday but the bulls could not build on the opening and the stock topped out at $7.17 for the day. The stock traded down to $6.96 during the day, due to lack of any buying support eventually closed down at $7.02 with a loss of -2.36% for the day. The stock had closed at $7.19 on the previous day. The total traded volume was 5,514,040 shares.
Also, Citigroup maintains their rating on the shares of Novavax (NASDAQ:NVAX). The current rating of the shares is Buy. Equity Analysts at the Firm raises the price target to $12 per share from $10 per share. The rating by the firm was issued on July 28, 2016.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).